This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, K.-H. Articles by Heo, D. S. Search for Related Content PubMed PubMed Citation Articles by Lee, K.-H. Articles by Heo, D. S.

High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy

Authors' Affiliations: ¹ Department of Internal Medicine and ² Nuclear Medicine, Seoul National University Hospital; and ³ Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Requests for reprints: Dae Seog Heo, Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea. Phone: 82-2-2072-2857; Fax: 82-2-742-6689; E-mail: heo1013{at}plaza.snu.ac.kr.

Purpose: To evaluate response and survival for platinum-based combination chemotherapy in chemonaive patients with non–small cell lung cancer (NSCLC) according to pretreatment standardized uptake values (SUV) by fluorodeoxyglucose positron emission tomography.

Experimental Design: Patients with advanced NSCLC who had not previously received chemotherapy were eligible. Response rates and survivals were analyzed according to maximal SUVs [low (7.5) versus high (>7.5), where 7.5 was the median value] before the first cycle of chemotherapy.

Results: Eighty-five consecutive patients were included in the retrospective study. Patients with high SUV tumors exhibited significantly higher response rates (34.1% for low SUVs versus 61.0% for high SUVs; P = 0.013). Other factors, including sex, age, histology, performance status, number of involved organs, regimens used, and disease stage, did not affect response. However, high SUVs were related with a shorter response duration (279 days for low SUVs versus 141 days for high SUVs; P = 0.003) and time to progression (282 days for low SUVs versus 169 days for high SUVs; P = 0.015). Overall survival was unaffected by maximal SUVs (623 days for low SUVs versus 464 days for high SUVs; P = 0.431).

Conclusions: Patients having NSCLC with high maximal SUVs showed a better response to platinum-based combination chemotherapy but had a shorter time to progression. Tumor glucose metabolism, as determined by SUVs on fluorodeoxyglucose positron emission tomography, was found to discriminate NSCLC subsets with different clinical and biological features.

This article has been cited by other articles:

				I. I. Na, B. H. Byun, H. J. Kang, G. J. Cheon, J. S. Koh, C. H. Kim, D. H. Choe, B.-Y. Ryoo, J. C. Lee, S. M. Lim, et al. 18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2008; 14(7): 2036 - 2041. [Abstract] [Full Text] [PDF]

				W. A. Weber, J. Czernin, and M. E. Phelps Prognostic Significance of Fluorodeoxyglucose Uptake in Non-Small Cell Lung Cancer. A Blurry Picture? Clin. Cancer Res., June 1, 2007; 13(11): 3105 - 3106. [Full Text] [PDF]